HanAll Signs Exclusive Licensing Agreement with Turn Biotechnologies

HanAll Biopharma Co. Ltd. has signed an exclusive licensing agreement with Turn Biotechnologies Inc., a pre-clinical stage biopharmaceutical company focused on cellular repair through epigenetic reprogramming—expanding their relationship, which began in 2022 when HanAll made an initial investment in Turn Bio.

The terms grant HanAll the right to utilize Turn Bio’s Epigenetic Reprogramming of Aging (ERATM) technology to research, develop, manufacture, and commercialize medicines for ophthalmic and otic disease.

HanAll anticipates leveraging synergies between ophthalmic and otic fields where it has therapeutic expertise and experience, and drawing on Turn Bio’s knowledge of cellular reprogramming, mRNAs, and lipid nanoparticles.

Addressing Age-Related Conditions

Aging mitigation and cell reprogramming technologies have recently received attention for their potential to address the high unmet needs in age-related disorders, particularly in the eye and ear. HanAll has been actively exploring cell reprogramming through open collaborations and a global network.

The ERATM technology developed by Turn Bio reverses certain aspects of cellular aging by utilizing a cocktail of mRNA transcription factors specifically designed for transient epigenetic reprogramming. Currently, Turn Bio is undertaking pre-clinical research for dermatology and immunology applications.

“We’re excited to advance into a new phase of development with Turn Bio to explore the potential of its innovative platform in addressing important age-related conditions. This partnership will enhance HanAll’s R&D capabilities in mRNA and LNP product development while also providing an opportunity to explore the potential for pipeline expansion,” said Sean Jeong, M.D., MBA, CEO of HanAll Biopharma.

“This agreement is a testament to the vast opportunities ahead globally as the world’s population grows older,” said Turn Bio CEO Anja Krammer. “HanAll’s commitment is recognition that our innovative ERA technology has the potential to revolutionize treatments for myriad conditions associated with aging.”

The deal, valued at over $300 million for the first product, is structured around negotiated milestones.

Source:
https://www.contractpharma.com/contents/view_breaking-news/2024-05-28/hanall-signs-exclusive-licensing-agreement-with-turn-biotechnologies/9769

PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.

Related News

Related Services